Decitabine

For research use only.

Catalog No.S1200 Synonyms: Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR

91 publications

Decitabine Chemical Structure

CAS No. 2353-33-5

Decitabine (Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 155 In stock
USD 90 In stock
USD 170 In stock
USD 320 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Decitabine has been cited by 91 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description Decitabine (Deoxycytidine, Dacogen, 5-aza-2-deoxycytidine, 5-AZA-dC, 5-aza-CdR) is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS). Decitabine induces cell cycle arrest and apoptosis in various cancer cell lines.
Targets
DNA methylation [1]
(HL-60, KG1a cells)
In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. [1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [3H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M{C1b2Z2dmO2aX;uJGF{e2G7 M4G1R|AvPcLizszN MkK1NlQhcA>? Mnnve4F1\XJ? NGPLRnFud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>? M4n0TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN|A5OjxxYU6=
Eca109 M3v0[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf5U2Q{OC53L{KuOU82KM7:TR?= M{DTVlI1NzR6L{eyJIg> MWn3ZZRmeg>? NEPqbVRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MnrmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMkOwPFIoRjJ3MUKzNFgzRC:jPh?=
Eca109 NX6zd4R4TnWwY4Tpc44hSXO|YYm= NXf5V5BuOC53wrFOwG0> M2m5NFYwOTJxMkSgbC=> NXy4d5FXf2G2ZYK= NGLRdFJqdmirYnn0d{Bk\WyuIH3p[5JifGmxbtMg NVPuVIQzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNlMxQDJpPkK1NVI{ODh{PD;hQi=>
Eca109 NGrGbZlHfW6ldHnvckBCe3OjeR?= NGSzPGIxNjYEoN88US=> NFTkZW0zPCCq NGSzdld4[XSnch?= MVrpcohq[mm2czDj[YxtKGmwdnHzbY9v M2TqNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN|A5OjxxYU6=
Eca109 NH7rUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rOc|AvPcLizszN NX:zWHN1OjRiaB?= NH2ySlV4[XSnch?= NV7lTFN[cW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>? MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTF{M{C4Nkc,OjVzMkOwPFI9N2F-
Eca109 Mnf3SpVv[3Srb36gRZN{[Xl? MV2wMlUwOSEQvF2= NGHMRVEzPCCq MlHke4F1\XJ? MkDP[IVkemWjc3XzJIV5eHKnc4Ppc44hd2ZiTl[t{tpDOiCjbnSgUW1ROg>? M4DoVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUKzNFgzLz5{NUGyN|A5OjxxYU6=
SW1116  NGnNfIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;6ZVAvPS9zL{KvOUDPxE1? NFnVR5g1QCCq MYrEUXNQ NUO5XZJr\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? M3LQ[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEe0Nlg3Lz5{NEi3OFI5PjxxYU6=
LOVO M2T4TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGS3S28xNjVxMT:yM|Uh|ryP NIPzPIU1QCCq NH:1NXJFVVOR MlzX[Y5p[W6lZYOgeIhmKEenZnn0bY5q[iCrbnT1Z4VlKGOnbHygbY5pcWKrdHnvci=> NGnWPJM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi3OFI5Pid-MkS4O|QzQDZ:L3G+
SW1116  MV\GeY5kfGmxbjDBd5NigQ>? MmrhNVAh|ryP MVW0PEBp NYX5OmdvTE2VTx?= NVjLcYplcW6lcnXhd4V{KHSqZTDl[oZm[3SrdnWgZZQhcW6qaXLpeIlv\yCDS2SgZY5lKG2WT2Kgd4lodmGuaX7nJJBifGi5YYnzJINwdWKrbnXkJJdqfGhiZ3XmbZRqdmmk MnTWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6N{SyPFYoRjJ2OEe0Nlg3RC:jPh?=
LOVO M4ThNGZ2dmO2aX;uJGF{e2G7 NYXFNWM3OTBizszN MnHrOFghcA>? Mnr2SG1UVw>? NI\STYxqdmO{ZXHz[ZMhfGinIHXm[oVkfGm4ZTDheEBqdmirYnn0bY5oKEGNVDDhcoQhdVSRUjDzbYdv[WyrbnegdIF1cHejeYOgZ49u[mmwZXSge4l1cCCpZX\peIlvcWJ? NWTJVldkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|QzQDZpPkK0PFc1Ojh4PD;hQi=>
SW1116  MmLIRZBweHSxc3nzJGF{e2G7 MmTUNVAh|ryP MYG0PEBp NWjpcXVVTE2VTx?= NHP2[XNmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> NUPhPWJTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4O|QzQDZpPkK0PFc1Ojh4PD;hQi=>
LOVO NHfWT5ZCeG:ydH;zbZMhSXO|YYm= MVixNEDPxE1? MX20PEBp NFLodmJFVVOR MnfM[Y5p[W6lZYOgS4VncXSrbnniMYlv\HWlZXSgZZBweHSxc3nz MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh5NEK4Okc,OjR6N{SyPFY9N2F-
RPMI-8226 MoXURZBweHSxc3nzJGF{e2G7 NYjvOIF1OS9{IN88US=> MXe0PE84Oi97NjDo NITsZplFVVOR NUj2UVdGcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
OPM-2  NGj0c2FCeG:ydH;zbZMhSXO|YYm= NUiybFh6OS9{IN88US=> NVj4WmpbPzJxOU[vNVIxKGh? MmG2SG1UVw>? M2rjSolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NV;mOHZTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
JJN3  MVvBdI9xfG:|aYOgRZN{[Xl? NXvVO3JSOC53L{Gg{txO MWSyOE81QCCq M1nNdGROW09? MVXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NV3JboxMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
NCI-H929  NHfZc2VCeG:ydH;zbZMhSXO|YYm= M{\5WlEwOiEQvF2= M3HMRVczNzl4L{GyNEBp NVyxUI17TE2VTx?= NFuy[pFqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NXrjPYVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
RPMI-8226 M3jFZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTMPFQyNzJizszN MV:yOE81QC95MjDo MoCzSG1UVw>? NEP4SnBi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MnzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6M{OxNFgoRjJ2OEOzNVA5RC:jPh?=
OPM-2  NYr1VnVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;GVFEwOiEQvF2= MkHiNlQwPDhxN{KgbC=> MWLEUXNQ NIjwdYRi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NGDG[2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEizN|ExQCd-MkS4N|MyODh:L3G+
JJN3  NXvi[G45T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHYeFRsOC53L{Gg{txO NXvyR|VOOjRxNEivO|IhcA>? M4jR[2ROW09? NH;3b|hi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NX7SU5liRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4N|MyODhpPkK0PFM{OTB6PD;hQi=>
NCI-H929  MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6yW3IyNzJizszN Mn7ONlQwPDhxN{KgbC=> MkG1SG1UVw>? NVrxSYR1[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh|M{GwPEc,OjR6M{OxNFg9N2F-
HeLa M{XpSGtqdmG|ZTDBd5NigQ>? NFrxdWJMcT1zMECw5qCUPTByMDFOwG0h\m:{IHjFUnQy NG\CZVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4NFA6QCd-MkS3PFAxQTh:L3G+
HeLa M4jl[2tqdmG|ZTDBd5NigQ>? NFm4bGdMcT13Lk[gxtEhOC53IN88UUBnd3JiaFXOWFI> NFr6U|E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEe4NFA6QCd-MkS3PFAxQTh:L3G+
HeLa NYr1fGNpU2mwYYPlJGF{e2G7 NW\5VmVCU2l;MkGuOkDDuSB|LkCg{txOKG[xcjDoR25VOQ>? M{HCW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2N{iwNFk5Lz5{NEe4NFA6QDxxYU6=
HeLa M4\3WGtqdmG|ZTDBd5NigQ>? MkjpT4k:OTRwNDFCtUA1NjZizszNJIZweiCqQ17UNy=> Ml;SQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5OECwPVgoRjJ2N{iwNFk5RC:jPh?=
NB4 NYDlTphGTnWwY4Tpc44hSXO|YYm= M4PzOVIvPS93L{euOU8yOCEQvF2= NGLCXFAzPCCq M3;vfWROW09? NHOyRoFqdmO{ZXHz[YEhfGinIHX4dJJme3Orb36gc4YheHKnY4Xyd49zKG2rUj2xNlVi MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR6NEi3NEc,OjR2OES4O|A9N2F-
CD4+ CD25− T  MknRSpVv[3Srb36gRZN{[Xl? MXixM|Uh|ryP M2HJUJJm\HWlZWOg[4xw[mGuIFTORUBu\XSqeXzheIlwdg>? NVnROGRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0O|Y{PjBpPkK0OFc3OzZyPD;hQi=>
BV-173 MmjKRZBweHSxc3nzJGF{e2G7 MUOwMlI2NzBwNT:wMlc2NzFizszN NUC0R|NSPDhxN{KvPVYhcA>? NX[2WpNZyqCSQmO= MlnQbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NI\4UJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
ML-1 M1uwWmFxd3C2b4Ppd{BCe3OjeR?= Mm\nNE4zPS9yLkWvNE44PS9zIN88US=> NVK4dY5ZPDhxN{KvPVYhcA>? MojixsBRSlN? NIrhXZVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NYjWXVE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
HL-60 M{i5dGFxd3C2b4Ppd{BCe3OjeR?= NWTvcW1FOC5{NT:wMlUwOC55NT:xJO69VQ>? NIjvdoM1QC95Mj:5OkBp M1vpeeKhWEKV NIXibpVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> M{fTdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
KG-1a MkLKRZBweHSxc3nzJGF{e2G7 MYmwMlI2NzBwNT:wMlc2NzFizszN NIK2SGU1QC95Mj:5OkBp M{TLW:KhWEKV NIfUfpBqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> NEjqUlE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NESyN|YyOyd-MkS0NlM3OTN:L3G+
BV-173 NXe5bpFXTnWwY4Tpc44hSXO|YYm= MnLQNlUxNzVyMH7N M{LPcVQ5KGh? M1XWOOKhWEKV M1Lw[Ylv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= M1;K[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
CEM M{TpZ2Z2dmO2aX;uJGF{e2G7 MknBNlUxNzVyMH7N NX7GWoUxPDhiaB?= NWnVN3dXyqCSQmO= M{XvWIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= M1LJclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
HL-60 M2HFZ2Z2dmO2aX;uJGF{e2G7 MnnMNlUxNzVyMH7N MYe0PEBp MXZCpHBDWw>? MVfpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? M{fnOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
ML-1 MojLSpVv[3Srb36gRZN{[Xl? MWeyOVAwPTBybl2= NXLXbWJDPDhiaB?= MWlCpHBDWw>? NXHVcYFRcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl M17LfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEKzOlE{Lz5{NESyN|YyOzxxYU6=
DLD-1 Mnq1SpVv[3Srb36gRZN{[Xl? NGO0PFIzPTBxNUCwcm0> NELrUVM1QCCq MWRCpHBDWw>? MWrkc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm NUjsXYczRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NlM3OTNpPkK0OFI{PjF|PD;hQi=>
HCT-116 M13oOmZ2dmO2aX;uJGF{e2G7 Mmn0NlUxNzVyMH7N NV7ic2M{PDhiaB?= MkfqxsBRSlN? NH6zZWxldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDR{M{[xN{c,OjR2MkO2NVM9N2F-
U937-A/E-9/14/18  MkfQRZBweHSxc3nzJGF{e2G7 MWWwMlAyNzBwMT:xM|ExKM7:TR?= NWPwWHZbPDhiaB?= NWDENmdrcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXn3d4d4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzNFA1PTZpPkK0N|AxPDV4PD;hQi=>
HT29 NI\ycIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\rVVczKGh? MXvJR|UxRTF2MEFCtVE4QSEQvF2= MmC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzN{KwOlEoRjJ2MUeyNFYyRC:jPh?=
SW48 MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXRO|IhcA>? NGC3UHJKSzVyPUG1MlLDuTZwMjFOwG0> M1\ueFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUeyNFYyLz5{NEG3NlA3OTxxYU6=
HCT116 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULu[5B7PzJiaB?= MXrJR|UxRTFwN9MxNE41KM7:TR?= NHvhUHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG3NlA3OSd-MkSxO|IxPjF:L3G+
HepG2 NUX6O5hITnWwY4Tpc44hSXO|YYm= MV[wMlUwOSEQvF2= MU[yOEBp M4PVU2ROW09? NVj4dWZNfXBvcnXneYxifGWmIITo[UBz\WyjdHn2[UBQS1SQMjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36= NEG5V2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG0Olg4PCd-MkSxOFY5PzR:L3G+
LS174T MVrGeY5kfGmxbjDBd5NigQ>? MmDmNE42NzFizszN M2DjNFI1KGh? M1;DWGROW09? NF3zS5Bt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=> NE\QcJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG0Olg4PCd-MkSxOFY5PzR:L3G+
HepG2 NUTFc29HSXCxcITvd4l{KEG|c3H5 NVHZZ|NLOS9zMD:xNFAh|ryP MWq3JIQ> NH\vXVJFVVOR NH7NRXVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MlT1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O|QoRjJ2MUS2PFc1RC:jPh?=
LS174T NILKbFlCeG:ydH;zbZMhSXO|YYm= MmrkNU8yOC9zMECg{txO NWX2VJdZPyCm NIi2SWdFVVOR MVvpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mnf1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzNE[4O|QoRjJ2MUS2PFc1RC:jPh?=
QBC-939 MnjVRZBweHSxc3nzJGF{e2G7 NEDTOYcyNzFyL{GwNEDPxE1? MXK3JIQ> NVLyOVVwTE2VTx?= MnTYbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M32zblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MUS2PFc1Lz5{NEG0Olg4PDxxYU6=
U251 NF7uWIRCeG:ydH;zbZMhSXO|YYm= NXHPVo9wOS9zMD:xNFAh|ryP MUW3JIQ> NXTh[Yo6TE2VTx?= MUjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NX3oZYE3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFY5PzRpPkK0NVQ3QDd2PD;hQi=>
HL-60 NG\DV3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqxJO69VQ>? NYHvTlA3PDhiaB?= NV7rZYM3cW6lcnXhd4V{KEd{LYDoZZNmKGOnbHyg[pJi[3Srb36= NIDkZWg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECwNFMzPCd-MkSwNFA{OjR:L3G+
MDA‑MB‑453 MXrGeY5kfGmxbjDBd5NigQ>? MoDqNE4zNzFizszN MYq3NkBp NE\3V2Jk[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> MnHRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN6NESyNlgoRjJ|OES0NlI5RC:jPh?=
HCC1569 Mn;uSpVv[3Srb36gRZN{[Xl? NGHjZncxNjJxMTFOwG0> NUjrVlc5PzJiaB?= M{LPToNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> NULqbmtMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO4OFQzOjhpPkKzPFQ1OjJ6PD;hQi=>
BT‑474 MXHGeY5kfGmxbjDBd5NigQ>? M{[1SFAvOi9zIN88US=> NIO5OZc4OiCq NFLGUY9k[XW|ZYOgdoUu\XiycnXzd4lwdiCxZjDjcIF2\GmwwrCxxsA> M32yNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|OES0NlI5Lz5{M{i0OFIzQDxxYU6=
AGS NYTTPZdNSXCxcITvd4l{KEG|c3H5 NF23SYg2NzFyL{KwM|UxKM7:TR?= MXe0POKhcMLi NHHabmpFVVOR MnT0bY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> NUftPIt6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PFI4QDRpPkKzOVgzPzh2PD;hQi=>
A549 MVrBdI9xfG:|aYOgRZN{[Xl? NUXGc3Q{PS9zMD:yNE82OCEQvF2= M2\ldlQ5yqCqwrC= M2\ETWROW09? MVTpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdIpCpC=> NGrOfIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W4Nlc5PCd-MkO1PFI4QDR:L3G+
AGS  NFrSempIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXmOU8yOC9{MD:1NEDPxE1? MnryOFjDqGkEoB?= MmLHSG1UVw>? NF\Ie5ZqdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA> Ml\KQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3OEK3PFQoRjJ|NUiyO|g1RC:jPh?=
Kasumi-1 MnflRZBweHSxc3nzJGF{e2G7 MnTJNE42KM7:TR?= MYC0POKhcMLi MYHk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= NWDoVYNJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVM{PDhpPkKzOFk{OzR6PD;hQi=>
OCI-AML3 NXvnVXFUSXCxcITvd4l{KEG|c3H5 MWGyMlUh|ryP NFvn[5E1QMLiaNMg NW\xXYxW\GWlcnXhd4V{KHSqZTDj[YxtKH[rYXLpcIl1gSClbz30doVifGWmIIfpeIghXGZvTmCtd4M> MnzDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2OUOzOFgoRjJ|NEmzN|Q5RC:jPh?=
MV4-11 MmDFRZBweHSxc3nzJGF{e2G7 M2K4R|IvPSEQvF2= NXLTZXVzPDkEoHlCpC=> MUHk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= M1jhXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEmzN|Q5Lz5{M{S5N|M1QDxxYU6=
NK  M2\xXWN6fG:2b4jpeJkhSXO|YYm= MmTsNE4xOi1{MDFOwG0> M3;oOVUh\A>? MV;k[YNz\WG|ZYOgeIhmKGO7dH;sfZRq[yCjY4Tpeol1gSCxZjDOT{Bk\WyuczDheEBqdnSncn3l[IlifGViY3;uZ4VvfHKjdHnvcpMhemW|dXz0bY5oKGmwIHGgWU1{cGGyZXSg[I9{\eLCk4Lld5BwdnOnIHP1dpZm MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN{OEC4PEc,OjN|MkiwPFg9N2F-
NK  MX3BdI9xfG:|aYOgRZN{[Xl? NEnDbHMxNjB{LUKwJO69VQ>? MmfpOUBl NWrKV|Bn\GWlcnXhd4UhVktiY3XscEBxem:uaX\ldoF1cW:wIHHu[EB3cWGkaXzpeJkh[XNidHjlJINwdmOnboTyZZRqd25iaX7jdoVie2Wm NHjNW449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OyPFA5QCd-MkOzNlgxQDh:L3G+
NK  NVS5XHhrTnWwY4Tpc44hSXO|YYm= NH;wcZoxNjBzLUKwJO69VQ>? MXO1JIQ> MkPvZ4F2e2W|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=> M3fnfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|M{K4NFg5Lz5{M{OyPFA5QDxxYU6=
MOLT4/DNR NV7DUJE4TnWwY4Tpc44hSXO|YYm= MYe1JO69VQ>? M{LNZlQh\A>? M2jmUpJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v Mk\5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkC1O|AoRjJ|ME[wOVcxRC:jPh?=
Jurkat/DOX M1L4XGZ2dmO2aX;uJGF{e2G7 M{e0clUh|ryP M4XHdlQh\A>? MnL0doVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44> M3\QR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
MOLT4/DNR MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\xdFFkPSEQvF2= MmPpOEBl M3Oz[JJm\HWlZYOgeIhmKEmFNUFCpJZidHWnIH\vdkBl[XWwb4L1ZolkcW5ic3Xud4l1cX[rdIm= MmDRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjNyNkC1O|AoRjJ|ME[wOVcxRC:jPh?=
Jurkat/DOX MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\4eZE2KM7:TR?= NXLrRVY{PCCm NGXqbG1z\WS3Y3XzJJRp\SCLQ{WwxsB3[Wy3ZTDmc5Ih\GG3bn;yeYJq[2mwIIPlcpNqfGm4aYT5 M{LV[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|ME[wOVcxLz5{M{C2NFU4ODxxYU6=
ccRCC  NYr1cJVlSXCxcITvd4l{KEG|c3H5 Mmi2NE4xOS1zMN88US=> M3PzeVczKGh? M2jmV2ROW09? M1Pz[IhieyCvaX7pcYFtKGWoZnXjeEBwdiClZXzsJJBzd2yrZnXyZZRqd25? NH7XRnc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
TNBC  M2rZSGFxd3C2b4Ppd{BCe3OjeR?= MkP1NE4xOS1zMN88US=> NVm4UY93PzJiaB?= M2Dp[WROW09? MVLoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v NFL1U5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
A498 NES3b5FCeG:ydH;zbZMhSXO|YYm= MnPkNE4xOS1zMN88US=> M1vSSlczKGh? MUDEUXNQ MmjYbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> NHnaWIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkiyOlQ3Pyd-MkK4NlY1Pjd:L3G+
KIJ265T NFviO3RCeG:ydH;zbZMhSXO|YYm= MVSwMlAyNTFyzszN NUW4eXBMPzJiaB?= MUTEUXNQ MmPGbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> MmfvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Mk[0OlcoRjJ{OEK2OFY4RC:jPh?=
MDA-231 NYmxVFJzSXCxcITvd4l{KEG|c3H5 MX[wMlAyNTFyzszN Mn7jO|IhcA>? MoDUSG1UVw>? NGHzU29qdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv Mo\aQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ6Mk[0OlcoRjJ{OEK2OFY4RC:jPh?=
BT-20 Ml\sRZBweHSxc3nzJGF{e2G7 NV7jVXUyOC5yMT2xNO69VQ>? MWe3NkBp MXjEUXNQ M3zEUYlv\HWlZYOgd5lv\XKpaYP0bYMhemW|cH;ud4V{yqC5aYToJJJwdWmmZYDzbY4> NXf5XHVKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4NlY1PjdpPkKyPFI3PDZ5PD;hQi=>
U937 Mm\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nLSVUuOjBizszN MmDsNlQwPDhxN{KgbC=> M4r5TIlv\HWlZYOgZUBl\WO{ZXHz[UBqdiClZXzsJJZq[WKrbHn0fUBqdiCjIHPvcoNmdnS{YYTpc44uKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
HL60 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOwcZczPS1{MDFOwG0> NEGxZpMzPC92OD:3NkBp NUfzXpFkcW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd4N{CyNUc,OjJ5NkewNlE9N2F-
U937 MVTBdI9xfG:|aYOgRZN{[Xl? NITibZEyPSEQvF2= Mo[5NlQwPDhxN{KgbC=> M3vYN4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NW\LXoI2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3OlcxOjFpPkKyO|Y4ODJzPD;hQi=>
HL60 M16wRmFxd3C2b4Ppd{BCe3OjeR?= NWLac5ZtOTVizszN NFLuNo0zPC92OD:3NkBp MV;pcoR2[2W|IHPlcIwh[XCxcITvd4l{ M3G2blxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{N{[3NFIyLz5{Mke2O|AzOTxxYU6=
LS411N  NVfHW3p[SXCxcITvd4l{KEG|c3H5 MWiwMlUh|ryP MojkO|IhcA>? NGHISmtqdmO{ZXHz[ZMhTmG|IH3SUmEhdGW4ZXy= NYSxV41ERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0OlE3QTVpPkKyOFYyPjl3PD;hQi=>
MDA-MB-231 MYDBdI9xfG:|aYOgRZN{[Xl? NYHhSHlsOTBizszN NXLocG9uPDhiaB?= M3HNUpJm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh6N{[5O{c,OjF6OEe2PVc9N2F-
MCF-7  NIjFOWFCeG:ydH;zbZMhSXO|YYm= NH;tN5kyOCEQvF2= NUHCRnA{PDhiaB?= M33yT5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NYPiWYhLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4PFc3QTdpPkKxPFg4Pjl5PD;hQi=>
A375 MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MViwMlUh|ryP MUexM|UwQCCm MYrpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? M{L3PFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
SKMEL1 M4m5UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\2TVAvPSEQvF2= NF;BXmMyNzVxODDk NHzIcYZqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MlS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5OU[2NlIoRjJzN{m2OlIzRC:jPh?=
SKMEL3 NVfz[IxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnZNE42KM7:TR?= MofFNU82NzhiZB?= M3rxd4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
SKMEL28 M2nBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfHO2E1OC53IN88US=> MlfDNU82NzhiZB?= MkCxbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
MeWo Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDsNE42KM7:TR?= Mn\6NU82NzhiZB?= MUHpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd7Nk[yNkc,OjF5OU[2NlI9N2F-
B16 MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13wU|AvPSEQvF2= MnSzNU82NzhiZB?= MXjpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? M2HaRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{m2OlIzLz5{MUe5OlYzOjxxYU6=
Ly 1 NVXi[oxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;LTI0zPCCq MV7JR|UxRTdwMzFOwG0> MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 7 MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;HPVI1KGh? M4XkWGlEPTB;MUCuO{DPxE1? MnfTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Su-DHL6 M1y5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7rNlQhcA>? NGToOGpKSzVy78{eNlAh|ryP NGDoTFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUe3NlA1QSd-MkG3O|IxPDl:L3G+
Ly 10 MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDBNlQhcA>? NHPPRnlKSzVy78{eNlAh|ryP M1zxelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
RIVA MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjp[WhlOjRiaB?= M1nGS2lEPTExvK6yNEDPxE1? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2 M{LXNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIiyO24zPCCq MmjkTWM2OO,:nkKwJO69VQ>? MnSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 1 NYDHfVU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTYN3M1QCCq NEC5NppKSzVyPUCuN|Qh|ryP MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 7 NHnCb4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7pXVM1QCCq NYnQ[ZJUUUN3ME2wMlAzPSEQvF2= MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL6 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjGTXUyPDhiaB?= NVvWUVVEUUN3MP-8olIxKM7:TR?= MkDIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 10 M1uze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T5XVQ5KGh? NGj6VlVKSzVyPUGuPEDPxE1? MlvFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
RIVA M3rwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mon5OFghcA>? M1HyU2lEPTExvK6yNEDPxE1? M3\sUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL2 NV7pelljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVS0PEBp MUHJR|UxRTF5LkSg{txO NVvKbI9SRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3O|IxPDlpPkKxO|czODR7PD;hQi=>
Ly 1 NX;SdZNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT1O|IhcA>? NUnXZpJ1UUN3ME2wMlAyKM7:TR?= Mo\BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
Ly 7 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfpcYY4OiCq NVrkOYJQUUN3ME2wMlAyQCEQvF2= M{PiPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{eyNFQ6Lz5{MUe3NlA1QTxxYU6=
Su-DHL6 MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mni3O|IhcA>? NGXZOXBKSzVyPUGuOkDPxE1? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Ly 10 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XWfFczKGh? MoPwTWM2OD1zLkKg{txO MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
RIVA NYj4fVVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn31O|IhcA>? M{TwcmlEPTExvK6yNEDPxE1? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd5MkC0PUc,OjF5N{KwOFk9N2F-
Su-DHL2 NUPkfXhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHmwWmo4OiCq NHLRPIFKSzVyPUGxMlIh|ryP MoXMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF5N{KwOFkoRjJzN{eyNFQ6RC:jPh?=
U373-MAGI M2S2XGFvfGm4aYLhcEBie3OjeR?= M3jvWlAvOjVidH:gPEB2VQ>? M1fZTlIhfG9iN{KgbJJ{ NX\T[G5zSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhXlOYLVegdJNmfWSxdInw[YQhUEmYLUGgUmw1NTNiaX7m[YN1\WRiaX6gbJVu[W5iVUO3N{1OSUeLIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBWPS2pYXegcIV3\WxiYYSgNE4zPSC2bzC4JJVOKGGodHXyJFIhfG9iN{KgbJJ{KGK7IIHQR3IhdWW2aH;k M2TsclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUG3NlYxLz5{N{GxO|I3ODxxYU6=
U373-MAGI M4PtXGFvfGm4aYLhcEBie3OjeR?= MoXMNE4zPSC2bzC4JJVO NF\yeHIzKHSxIEeyJIhzew>? M17wSWFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JHZUXi2JIIDz[ZVld3S7cHXkJGhKXi1zIF7MOE0{KGmwZnXjeIVlKGmwIHj1cYFvKFV|N{OtUWFIUSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6g[4FoKGyndnXsJIF1KDBwMkWgeI8hQCC3TTDh[pRmeiB{IITvJFczKGi{czDifUByWEOUIH3leIhw\A>? Mk\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzMUeyOlAoRjJ5MUG3NlYxRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
Survivin / Bcl-2 / p53 / c-Myc / DNMT1; 

PubMed: 26384351     


HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells.

p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; 

PubMed: 25762617     


Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations.

phospho-p38 / p38 / phospho-NFκB / NFκB; 

PubMed: 26617834     


Decitabine suppressed the phosphorylation of p38 and NF-κB.

p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; 

PubMed: 26692933     


DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments.

E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; 

PubMed: 28152502     


The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.

26384351 25762617 26617834 26692933 28152502
Immunofluorescence
DNMT1; 

PubMed: 21303982     


Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain).

E-cadherin / MMP-9; 

PubMed: 28152502     


Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC. 

21303982 28152502
Growth inhibition assay
Cell viability; 

PubMed: 26384351     


Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.

26384351
In vivo In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. [2]

Protocol

Kinase Assay:[1]
- Collapse

DNA synthesis assay :

The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [3H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:[1]
- Collapse
  • Cell lines: HL-60 and KG1a
  • Concentrations: 0-500 nM
  • Incubation Time: 96 hours
  • Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice.
  • Dosages: ≤2.5 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
water
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 228.21
Formula

C8H12N4O4

CAS No. 2353-33-5
Storage powder
in solvent
Synonyms Deoxycytidine, Dacogen, 5-aza-2'-deoxycytidine, 5-AZA-dC, 5-aza-CdR
Smiles C1C(C(OC1N2C=NC(=NC2=O)N)CO)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04086238 Completed Drug: Decitabine Healthy EpiDestiny Inc. October 8 2019 Phase 1
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03875287 Recruiting Drug: Decitabine|Drug: Cedazuridine Solid Tumor Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Astex Pharmaceuticals Inc. April 17 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is S1200 a racemic mixture or a monomer?

  • Answer:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: buy Decitabine | Decitabine supplier | purchase Decitabine | Decitabine cost | Decitabine manufacturer | order Decitabine | Decitabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID